Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ItAlian, Multicenter, Observational, Prospective sTudy to Evaluate the acHievement of Clinical rEmission and immuNomodulation in Severe Eosinophilic Asthma Patients Treated With Benralizumab - the ATHENA Study

NCT07214753 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07214753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07214753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ItAlian, Multicenter, Observational, Prospective sTudy to Evaluate the acHievement of Clinical rEmission and immuNomodulation in Severe Eosinophilic Asthma Patients Treated With Benralizumab - the ATHENA Study
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
December 20, 2025
Completion date
December 31, 2028
Enrollment
335 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

severe eosinophilic asthma